Skip to Main Content

An official website of the United States government

Here you can browse the complete list of projects for PLCO whose requests for data/biospecimens were approved.

Name Principal Investigator Institution Study Date Approved Project ID
Transfer Learning for Disease Diagnosis and Therapy Development Herschel Rabitz Princeton University PLCO Aug 8, 2023 PLCO-1279
Exploring the Viability of New Technology to Quickly Determine All Feature Contributions, Feature Value Contributions, Feature Interactions, and Feature Value Interactions that lead to cancer. Victor McGuire Renown AI, Inc. PLCO Jul 19, 2023 PLCO-1275
Optimal and Fair Encouragement Designs Angela Zhou University of Southern California PLCO Jul 19, 2023 PLCO-1271
Role of directly measured metabolic profile as an intermediate between adiposity and endometrial cancer: triangulation of evidence from independent sources Laure Dossus The International Agency for Research on Cancer, World Health Organization (IARC) PLCO Jul 3, 2023 PLCO-1265
Characterizing the independent and joint contributions of the chemical, non-chemical, and social-structural environment on cancer incidence and mortality in the PLCO Study Jessica Madrigal Jessica Madrigal PLCO Jun 22, 2023 PLCO-1259
In Silico Testing of Hypotheses for the Effect of Smoking on Somatic Evolution in the Healthy Human Lung Sam Janes University College London PLCO Jun 22, 2023 PLCO-1258
Analyze the effectiveness of CA-125 to detect ovarian and non-ovarian cancer. Joel Sokol Georgia Institute of Technology PLCO Jun 13, 2023 PLCO-1253
Detection of frameshift mutations in microsatellite instable colorectal cancer in the PLCO Cancer Screening Trial Robert Shoemaker National Cancer Institute PLCO Jun 12, 2023 2023-0063
Environmental and Metabolic Phenotyping of the Blood Cancer Exposome Douglas Walker Emory University PLCO Jun 12, 2023 2023-0062
Quantifying the proteome: exploratory associations with hepatocellular carcinoma Eleanor Watts Eleanor L. Watts PLCO Jun 12, 2023 2023-0061
Characterizing the role of disruptive changes in native stromal architecture and cell composition in the etiopathogenesis and natural history of multi-state colorectal and prostate cancers Mustapha Abubakar Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, USA PLCO Jun 12, 2023 2023-0058
Validation of Pathways-Based Biomarkers for the Early Detection of Prediagnostic Pancreatic Adenocarcinoma in the Blood Ann Killary The University of Texas M. D. Anderson Cancer Center PLCO Jun 12, 2023 2023-0056
Ceramides as drivers of metabolic dysfunction and colorectal cancer risk Mary Playdon University of Utah and Huntsman Cancer Institute PLCO Jun 12, 2023 2023-0050
Competing risks model with application to lung cancer and breast cancer in PLCO Minjung Lee Kangwon National University PLCO Jun 6, 2023 PLCO-1248
Survival Curves for Hierarchical Data Ali Parsaee University of Alberta PLCO May 30, 2023 PLCO-1241
Two-phase designs with failure time processes subject to non-susceptibility Li Cheung Li Chien Cheung PLCO May 30, 2023 PLCO-1238
Association of HLA Diversity With All-Cause Mortality in PLCO Zhiwei Liu National Cancer Institute PLCO May 30, 2023 PLCO-1227
Absolute risk from nested case-control data Mitchell Gail National Cancer Institute, National Institutes of Health PLCO May 5, 2023 PLCO-1218
Identification of genetic and lifestyle determinants of estrogen metabolism profiles Fangcheng Yuan Vanderbilt University Medical Center PLCO Apr 19, 2023 PLCO-1199
Developing an Accurate and Interpretable Risk-Based Model for Lung Cancer Screening Yi Luo Moffitt Cancer Center PLCO Apr 19, 2023 PLCO-1205